<DOC>
	<DOCNO>NCT01830595</DOCNO>
	<brief_summary>Our general goal evaluate potential effectiveness recombinant lactoferrin ( 1500mg bid ) reduce inflammation among HIV positive participant .</brief_summary>
	<brief_title>Lactoferrin Treatment HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>1 . HIVpositive participant receive ART &gt; 1 year 2 . HIV RNA level &lt; 200 copies/mL least 6 month ( â‰¥2 separate value ) 3 . Age &gt; 40 year 1 . Prior cardiovascular disease stroke 2 . Diabetes 3 . Rheumatologic Diseases 4 . Pregnancy 5 . Chronic kidney disease , stage IV V ( creatinine clearance &lt; 30 mL/min/1.73m2 ) 6 . Cirrhosis endstage liver disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>